ArticleFrontiers in oncology2022

Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.

Yin Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.